Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIFI-Jr phase 3 ustekinumab study in pediatric ulcerative colitis
MOH_2023-01-31_012321Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in autoimmune colitis (3 arms), sponsored by Janssen Pharmaceutical. Started Jan 2023; status: completed.
02
Drugs
ustekinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2023-01-31_012321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-31_012321.